Incyte Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bill Meury
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.4yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 31
Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio
Oct 28Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Aug 14Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings
Aug 06Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues
Apr 30Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Mar 18Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Feb 11Incyte: Multiple Drug Launches Bode Well For Future Growth
Jan 11Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Oct 31
Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas
Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Aug 19Incyte: The Worst Has Been Avoided
Jun 16Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27CEO
Bill Meury (57 yo)
Mr. William Meury, also known as Bill, served as the Chief Executive Officer & Director of Anthos Therapeutics, Inc. since April 2024. He is CEO, President & Director of Incyte Corporation from June 26, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President and Head of Research & Development | 2.4yrs | US$7.90m | 0.0026% $ 473.7k | |
| Advisor to CEO & Director | less than a year | US$17.46m | 0.23% $ 40.9m | |
| Executive VP & Chief Medical Officer | 10.6yrs | US$5.98m | 0.0013% $ 235.0k | |
| CEO, President & Director | less than a year | no data | no data | |
| Principal Financial Officer | 3.6yrs | no data | 0.0047% $ 842.6k | |
| Executive VP & Head of Global Technical Operations | 9.8yrs | no data | 0.028% $ 5.0m | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive VP | 2yrs | no data | 0.00033% $ 59.7k | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | less than a year | no data | no data | |
| Group VP | no data | no data | no data | |
| VP & Head of Global Communications | 3.8yrs | no data | no data |
Experienced Management: INCY's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Advisor to CEO & Director | 11.8yrs | US$17.46m | 0.23% $ 40.9m | |
| CEO, President & Director | less than a year | no data | no data | |
| Independent Director | 10.8yrs | US$518.15k | 0.0093% $ 1.7m | |
| Independent Chairman of the Board | 23.9yrs | US$552.15k | 0.14% $ 25.7m | |
| Independent Director | 4.1yrs | US$494.15k | 0.0044% $ 804.6k | |
| Independent Director | 8.8yrs | US$505.65k | 0.0086% $ 1.5m | |
| Independent Director | 5.8yrs | US$521.65k | 0.0092% $ 1.7m | |
| Independent Director | 5.6yrs | US$494.15k | 0.0055% $ 996.2k | |
| Independent Director | 10.8yrs | US$519.15k | 0.011% $ 1.9m | |
| Independent Director | 3yrs | US$503.88k | 0.0025% $ 448.4k |
Experienced Board: INCY's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 04:29 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Incyte Corporation is covered by 50 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Ying Huang | Barclays |